From: The prognosis of hepatoid adenocarcinoma of the stomach: a propensity score-based analysis
Factors | Before propensity matching | After 1:1propensity matching | After 1:2 propensity matching | ||||||
---|---|---|---|---|---|---|---|---|---|
Non-HAS | HAS | P value* | Non-HAS | HAS | P value | Non-HAS | HAS | P value | |
(n = 711) | (n = 73) | n = 72 | N = 72 | n = 110 | n = 55 | ||||
No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | ||||
Sex (M/F) | 509/202 | 60/13 | 0.053 | 60/12 | 59/13 | 0.826 | 87/23 | 44/11 | 0.892 |
Age (median) (yr))# | 59 (24-84) | 58 (26-76) | 0.720 | 62 (31-81) | 58 (26-76) | 0.155 | 58 (36-80) | 60 (26-76) | 0.136 |
 <45 | 78 (11.0) | 7 (9.6) |  | 3 (4.2) | 7 (9.7) |  | 12 (10.9) | 5 (9.1) |  |
 60>age≥45 | 278 (39.1) | 32 (43.8) |  | 26 (36.1) | 31 (43.1) |  | 50 (45.5) | 22 (40.0) |  |
 ≥60 | 355 (49.9) | 34 (46.6) |  | 43 (59.7) | 34 (47.2) |  | 48 (43.6) | 28 (50.9) |  |
Locationa | Â | Â | 0.364 | Â | Â | 0.640 | Â | Â | 0.785 |
 U | 217 (30.5) | 25 (34.2) |  | 19 (26.4) | 24 (33.3) |  | 39 (35.5) | 19 (34.5) |  |
 M | 126 (17.7) | 9 (12.3) |  | 11 (15.3) | 9 (12.5) |  | 11 (10.0) | 7 (12.7) |  |
 L | 360 (50.6) | 39 (53.4) |  | 42 (58.3) | 39 (54.2) |  | 59 (53.6) | 29 (52.7) |  |
 T | 8 (1.1) | 0 (0.0) |  | 0 (0.0) | 0 (0.0) |  | 1 (0.9) | 0 (0.0) |  |
Surgery type | Â | Â | 0.584 | Â | Â | 1.000 | Â | Â | 0.445 |
 PG | 9 (1.3) | 2 (2.7) |  | 0 (0.0) | 1 (0.7) |  | 1 (0.9) | 2 (3.6) |  |
 DG | 350 (49.2) | 39 (53.4) |  | 42 (58.3) | 40 (56.9) |  | 55 (50.0) | 30 (54.5) |  |
 TG | 349 (49.1) | 32 (43.8) |  | 30 (41.7) | 31 (42.4) |  | 53 (48.2) | 23 (41.8) |  |
 TGC | 3 (0.4) | 0 (0.0) |  | 0 (0.0) | 0 (0.0) |  | 1 (0.9) | 0 (0.0) |  |
Vascular invasion | Â | Â | 0.328 | Â | Â | 0.074 | Â | Â | 0.315 |
 no | 325 (45.7) | 29 (39.7) |  | 18 (25.0) | 28 (38.9) |  | 49 (44.5) | 20 (36.4) |  |
 yes | 386 (54.3) | 44 (60.3) |  | 54 (75.0) | 44 (61.1) |  | 61 (55.5) | 35 (63.6) |  |
T | Â | Â | 0.004 | Â | Â | 0.051 | Â | Â | 0.990 |
 Tis, T0, T1, T2 | 171 (24.0) | 21 (28.8) |  | 18 (25.0) | 20 (27.8) |  | 34 (30.9) | 17 (30.9) |  |
 T3 | 260 (36.6) | 39 (53.4) |  | 26 (36.1) | 37 (51.4) |  | 51 (46.4) | 26 (47.3) |  |
 T4 | 280 (39.4) | 13 (17.8) |  | 28 (38.9) | 15 (20.8) |  | 25 (22.7) | 12 (21.8) |  |
N | Â | Â | 0.180 | Â | Â | 0.182 | Â | Â | 0.566 |
 N0 | 221 (31.1) | 11 (15.1) |  | 12 (16.7) | 11 (15.3) |  | 29 (26.4) | 11 (20.0) |  |
 N1 | 154 (21.7) | 23 (31.5) |  | 18 (25.0) | 23 (31.9) |  | 24 (21.8) | 17 (30.9) |  |
 N2 | 143 (20.1) | 22 (30.1) |  | 14 (19.4) | 23 (31.9) |  | 30 (27.3) | 13 (23.6) |  |
 N3 | 293 (27.1) | 17 (23.3) |  | 28 (38.9) | 15 (20.8) |  | 27 (24.5) | 14 (25.5) |  |
M | Â | Â | Â | Â | Â | 1.00 | Â | Â | 1.000 |
 M0 | 711 (100) | 73 (100) |  | 69 (95.8) | 70 (97.2) |  | 109 (99.1) | 54 (98.2) |  |
 M1 | 0 | 0 |  | 3 (4.2) | 2 (2.8) |  | 1 (0.9) | 1 (1.8) |  |
EGFR | Â | Â | <0.001 | Â | Â | 0.940 | Â | Â | 0.695 |
 - | 64 (9.0) | 2 (2.7) |  | 1 (1.4) | 2 (2.8) |  | 6 (5.5) | 2 (3.6) |  |
 + | 259 (36.4) | 6 (8.2) |  | 16 (22.2) | 7 (9.7) |  | 10 (9.1) | 7 (12.7) |  |
 ++ | 195 (27.4) | 36 (49.3) |  | 23 (31.9) | 37 (51.4) |  | 46 (41.8) | 26 (47.3) |  |
 +++ | 193 (27.1) | 29 (39.7) |  | 32 (44.4) | 26 (36.1) |  | 48 (43.6) | 20 (36.4) |  |
Ki-67 | Â | Â | 0.003 | Â | Â | 0.648 | Â | Â | 0.741 |
 0-25% | 65 (9.1) | 5 (6.8) |  | 3 (4.2) | 5 (6.9) |  | 10 (9.1) | 5 (9.1) |  |
 26-50% | 168 (23.6) | 5 (6.8) |  | 10 (13.9) | 6 (8.3) |  | 12 (10.9) | 6 (10.9) |  |
 51-75% | 208 (29.3) | 25 (34.2) |  | 18 (25.0) | 24 (33.3) |  | 41 (37.3) | 16 (29.1) |  |
 76-100% | 270 (38.0) | 38 (52.1) |  | 41 (56.9) | 37 (51.4) |  | 47 (42.7) | 28 (50.9) |  |
CEA (ng/ml) | Â | Â | <0.001 | Â | Â | 0.384 | Â | Â | 0.266 |
 ≤5 | 575 (80.9) | 45 (61.6) |  | 49 (68.1) | 44 (61.1) |  | 77 (70.0) | 43 (78.2) |  |
 >5 | 136 (19.1) | 28 (38.4) |  | 23 (31.9) | 28 (38.9) |  | 33 (30.0) | 12 (21.8) |  |
CA199 (u/ml) | Â | Â | 0.026 | Â | Â | 0.347 | Â | Â | 0.716 |
 ≤37 | 604 (85.0) | 69 (94.5) |  | 65 (90.3) | 68 (94.4) |  | 105 (95.5) | 51 (92.7) |  |
 >37 | 107 (15.0) | 4 (5.5) |  | 7 (9.7) | 4 (5.6) |  | 5 (4.5) | 4 (7.3) |  |
Her-2 | Â | Â | 0.012 | Â | Â | 0.962 | Â | Â | 0.883 |
 -/+ | 533 (75.0) | 43 (58.9) |  | 43 (59.7) | 43 (59.7) |  | 74 (67.3) | 35 (63.6) |  |
 +++ | 54 (7.6) | 10 (13.7) |  | 10 (13.9) | 9 (12.5) |  | 10 (9.1) | 6 (10.9) |  |
 ++ | 124 (17.4) | 20 (27.4) |  | 19 (26.4) | 20 (27.8) |  | 26 (23.6) | 14 (25.5) |  |
neoadjuvant chemotherapy | Â | Â | 0.005 | Â | Â | 0.441 | Â | Â | 0.880 |
 no | 628 (88.3) | 56 (76.7) |  | 52 (72.2) | 56 (77.8) |  | 93 (84.5) | 46 (83.6) |  |
 yes | 83 (11.7) | 17 (23.3) |  | 20 (27.8) | 16 (22.2) |  | 17 (15.5) | 9 (16.4) |  |